Core Insights - The company announced promising preclinical efficacy results for its obesity treatment candidates ASC47 and ASC31, which are a combination of a novel GLP-1R/GIPR dual agonist and a selective THRβ agonist [1][2] Group 1: Drug Candidates - ASC31 is a novel GLP-1R and GIPR dual agonist peptide developed by the company, showing good pharmacokinetic characteristics in non-human primates and positive in vivo efficacy in DIO mice [1] - ASC47 is a fat-targeting, once-monthly subcutaneous THRβ selective small molecule agonist, which achieves high drug concentrations in adipose tissue in a dose-dependent manner [1] Group 2: Clinical Study Results - A study comparing low-dose ASC47 (9 mg/kg, subcutaneous) combined with ASC31 (3 nmol/kg, subcutaneous) versus ASC47 combined with teriparatide (3 nmol/kg, subcutaneous) over 14 days showed that the ASC47 and ASC31 combination resulted in an average weight loss of 44.8%, which is 17.6% more than the 38.1% weight loss observed with ASC47 and teriparatide [2] - The CEO highlighted the significant differentiation potential of the new therapy compared to existing weight loss drugs and other candidates in development, indicating a robust pipeline of obesity treatment options that include both small molecules and peptides [2]
歌礼制药-B：ASC47与GLP-1R/GIPR双受体激动剂多肽ASC31联用在肥胖动物模型中显示出优于ASC47与替尔泊肽联用的减重效果